Search

Your search keyword '"Hirsch I"' showing total 830 results
Start Over Author "Hirsch I"
830 results on '"Hirsch I"'

1. Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma

Author

O'Quinn S, Xu X, and Hirsch I

Subjects
asthma, benralizumab, eosinophils, interleukin-5 receptor, monoclonal antibody, patient-reported outcomes, Immunologic diseases. Allergy, RC581-607
Abstract

Sean O’Quinn, Xiao Xu, Ian Hirsch AstraZeneca, Gaithersburg, MD, USA Background: Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody that reduces exacerbations and improves asthma symptoms for patients with severe, uncontrolled eosinophilic asthma.Objective: The objective of this study was to evaluate improvements in daily asthma-related health status outcomes following treatment with benralizumab.Methods: Pooled results from the SIROCCO (NCT01928771) and CALIMA (NCT01914757) Phase III studies were analyzed. Patients aged 12–75 years with severe, uncontrolled asthma, and blood eosinophil counts (BEC) ≥300 and ≥150 cells/µL were evaluated. Patients received subcutaneous benralizumab 30 mg every 4 weeks (Q4W) or every 8 weeks (Q8W, first three doses Q4W) or placebo and completed a daily diary reporting rescue medication use, night-time awakening requiring rescue medication use, perceived tiredness, and asthma-related activity impairment. Outcome measures were compared across treatment arms from baseline to end of treatment (EOT) using a mixed-effect model for repeated measures analyses.Results: Patients with BEC ≥300 cells/µL receiving benralizumab Q8W had greater improvements in all patient-reported outcomes at EOT relative to baseline than patients receiving placebo (all nominal P≤0.013). Effects were reported as early as 3 days following the initial dose and sustained throughout treatment for daily and night-time rescue medication use and night-time awakenings requiring rescue medication. For patients with BEC ≥300 and ≥150 cells/µL, sustained improvements in activity impairment items (all nominal P

Published
2019

2. Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV

Author

Prunas, O., primary, Willemsen, J., additional, Warren, J.L., additional, Bont, L., additional, Schwartz, J.L., additional, Atwell, J., additional, Begier, E., additional, Dean, N., additional, Hirsch, I., additional, Karron, R., additional, Klugman, K., additional, Kramer, R., additional, Leidman, E., additional, Link-Gelles, R., additional, Nair, H., additional, Panozzo, CA., additional, Pelfrene, E., additional, Simões, E.A.F., additional, Smith, P.G., additional, Srikantiah, P., additional, Sundaram, M.E., additional, Thindwa, D., additional, Vaughn, D.W., additional, Wilson, E., additional, Zar, H.J., additional, Pitzer, V.E., additional, and Weinberger, D.M., additional

Published
2024
Full Text
View/download PDF

3. Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV

Author

Infectieziekten onderzoek1 (Bont), Infection & Immunity, CTI Bont, Zorg en O&O, Child Health, Prunas, O., Willemsen, J., Warren, J. L., Bont, L., Schwartz, J. L., Atwell, J., Begier, E., Dean, N., Hirsch, I., Karron, R., Klugman, K., Kramer, R., Leidman, E., Link-Gelles, R., Nair, H., Panozzo, CA A., Pelfrene, E., Simões, E. A.F., Smith, P. G., Srikantiah, P., Sundaram, M. E., Thindwa, D., Vaughn, D. W., Wilson, E., Zar, H. J., Pitzer, V. E., Weinberger, D. M., Infectieziekten onderzoek1 (Bont), Infection & Immunity, CTI Bont, Zorg en O&O, Child Health, Prunas, O., Willemsen, J., Warren, J. L., Bont, L., Schwartz, J. L., Atwell, J., Begier, E., Dean, N., Hirsch, I., Karron, R., Klugman, K., Kramer, R., Leidman, E., Link-Gelles, R., Nair, H., Panozzo, CA A., Pelfrene, E., Simões, E. A.F., Smith, P. G., Srikantiah, P., Sundaram, M. E., Thindwa, D., Vaughn, D. W., Wilson, E., Zar, H. J., Pitzer, V. E., and Weinberger, D. M.

Published
2024

6. 856P Characterization of patients with brain metastases from metastatic uveal melanoma

Author

Pimentel Muniz, T., primary, Koch, E.C., additional, Silva Almeida Ribeiro, M.F., additional, Silveira, M.T., additional, Arteaga Ceballos, D.P., additional, Jablonska, P.A., additional, Mantle, L., additional, Hirsch, I., additional, Krema, H., additional, Spreafico, A., additional, Saibil, S., additional, Hogg, D., additional, Shultz, D., additional, and Butler, M.O., additional

Published
2022
Full Text
View/download PDF

7. 831P Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp

Author

Koch, E.C., primary, Arteaga Ceballos, D.P., additional, Vilbert, M., additional, Lajkosz, K., additional, Pimentel Muniz, T., additional, Hirsch, I., additional, Silva Almeida Ribeiro, M.F., additional, Mantle, L., additional, Anczurowski, M., additional, Hogg, D., additional, Saibil, S., additional, Spreafico, A., additional, Krema, H., additional, and Butler, M.O., additional

Published
2022
Full Text
View/download PDF

8. 1687P Targeted metabolomics reveals dynamic changes and potential therapeutic targets in the serum metabolome of patients receiving adoptive cell therapy with tumor infiltrating lymphocytes

Author

Mantle, L., primary, Millar, D., additional, Laister, R., additional, Sotov, V., additional, Nguyen, L., additional, Robert, C., additional, Vilbert, M., additional, Pimentel Muniz, T., additional, Hirsch, I., additional, Silva Almeida Ribeiro, M.F., additional, Koch, E.C., additional, Ohashi, P., additional, Butler, M.O., additional, and Saibil, S., additional

Published
2022
Full Text
View/download PDF

9. 834P Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)

Author

Silva Almeida Ribeiro, M.F., primary, Pimentel Muniz, T., additional, Jablonska, P., additional, Hirsch, I., additional, Vilbert, M., additional, Koch, E.C., additional, Mantle, L., additional, Saibil, S., additional, Spreafico, A., additional, Hogg, D., additional, Shultz, D., additional, and Butler, M.O., additional

Published
2022
Full Text
View/download PDF

15. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Author

Feng, S, Phillips, DJ, White, T, Sayal, H, Aley, PK, Bibi, S, Dold, C, Fuskova, M, Gilbert, SC, Hirsch, I, Humphries, HE, Jepson, B, Kelly, EJ, Plested, E, Shoemaker, K, Thomas, KM, Vekemans, J, Villafana, TL, Lambe, T, Pollard, AJ, Voysey, M, Adlou, S, Allen, L, Angus, B, Anslow, R, Asselin, M-C, Baker, N, Baker, P, Barlow, T, Beveridge, A, Bewley, KR, Brown, P, Brunt, E, Buttigieg, KR, Camara, S, Charlton, S, Chiplin, E, Cicconi, P, Clutterbuck, EA, Collins, AM, Coombes, NS, Clemens, SAC, Davison, M, Demissie, T, Dinesh, T, Douglas, AD, Duncan, CJA, Emary, KRW, Ewer, KJ, Felle, S, Ferreira, DM, Finn, A, Folegatti, PM, Fothergill, R, Fraser, S, Garlant, H, Gatcombe, L, Godwin, KJ, Goodman, AL, Green, CA, Hallis, B, Hart, TC, Heath, PT, Hill, H, Hill, AVS, Jenkin, D, Kasanyinga, M, Kerridge, S, Knight, C, Leung, S, Libri, V, Lillie, PJ, Marinou, S, McGlashan, J, McGregor, AC, McInroy, L, Minassian, AM, Mujadidi, YF, Penn, EJ, Petropoulos, CJ, Pollock, KM, Proud, PC, Provstgaard-Morys, S, Rajapaska, D, Ramasamy, MN, Sanders, K, Shaik, I, Singh, N, Smith, A, Snape, MD, Song, R, Shrestha, S, Sutherland, RK, Thomson, EC, Turner, DPJ, Webb-Bridges, A, Wrin, T, Williams, CJ, and Group, Oxford COVID Vaccine Trial

Subjects
Male, Antibodies, Viral, Neutralization, Cohort Studies, Multiplex, Asymptomatic Infections, 11 Medical and Health Sciences, Aged, 80 and over, Vaccines, biology, medicine.diagnostic_test, Vaccination, General Medicine, Middle Aged, Titer, Treatment Outcome, Infectious diseases, Female, Antibody, medicine.symptom, Adult, medicine.medical_specialty, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Adolescent, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Immunization, Secondary, Asymptomatic, General Biochemistry, Genetics and Molecular Biology, World health, Article, Young Adult, Immune system, Statistical significance, Internal medicine, medicine, Humans, Aged, Infection Control, business.industry, SARS-CoV-2, Patient Acuity, COVID-19, Vaccine efficacy, Antibodies, Neutralizing, United Kingdom, Immunity, Humoral, Immunoassay, biology.protein, business
Abstract

The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines., Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine ChAdOx1 nCoV-19 are identified as correlates of protection against symptomatic infection.

Published
2021

27. Serum urate lowering with allopurinol and kidney function in type 1 diabetes

Author

Doria, A., Galecki, A. T., Spino, C., Pop-Busui, R., Cherney, D. Z., Lingvay, I., Parsa, A., Rossing, P., Sigal, R. J., Afkarian, M., Aronson, R., Caramori, M. L., Crandall, J. P., De Boer, I. H., Elliott, T. G., Goldfine, A. B., Haw, J. S., Hirsch, I. B., Karger, A. B., Maahs, D. M., McGill, J. B., Molitch, M. E., Perkins, B. A., Polsky, S., Pragnell, M., Robiner, W. N., Rosas, S. E., Senior, P., Tuttle, K. R., Umpierrez, G. E., Wallia, A., Weinstock, R. S., Wu, Chunyi, Mauer, M., Doria, A., Galecki, A. T., Spino, C., Pop-Busui, R., Cherney, D. Z., Lingvay, I., Parsa, A., Rossing, P., Sigal, R. J., Afkarian, M., Aronson, R., Caramori, M. L., Crandall, J. P., De Boer, I. H., Elliott, T. G., Goldfine, A. B., Haw, J. S., Hirsch, I. B., Karger, A. B., Maahs, D. M., McGill, J. B., Molitch, M. E., Perkins, B. A., Polsky, S., Pragnell, M., Robiner, W. N., Rosas, S. E., Senior, P., Tuttle, K. R., Umpierrez, G. E., Wallia, A., Weinstock, R. S., Wu, Chunyi, and Mauer, M.

Abstract

BACKGROUND: Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease. METHODS: In a double-blind trial, we randomly assigned participants with type 1 diabetes, a serum urate level of at least 4.5 mg per deciliter, an estimated GFR of 40.0 to 99.9 ml per minute per 1.73 m2 of body-surface area, and evidence of diabetic kidney disease to receive allopurinol or placebo. The primary outcome was the baseline-adjusted GFR, as measured with iohexol, after 3 years plus a 2-month washout period. Secondary outcomes included the decrease in the iohexol-based GFR per year and the urinary albumin excretion rate after washout. Safety was also assessed. RESULTS: A total of 267 patients were assigned to receive allopurinol and 263 to receive placebo. The mean age was 51.1 years, the mean duration of diabetes 34.6 years, and the mean glycated hemoglobin level 8.2%. The mean baseline iohexol-based GFR was 68.7 ml per minute per 1.73 m2 in the allopurinol group and 67.3 ml per minute per 1.73 m2 in the placebo group. During the intervention period, the mean serum urate level decreased from 6.1 to 3.9 mg per deciliter with allopurinol and remained at 6.1 mg per deciliter with placebo. After washout, the between-group difference in the mean iohexol-based GFR was 0.001 ml per minute per 1.73 m2 (95% confidence interval [CI], -1.9 to 1.9; P = 0.99). The mean decrease in the iohexol-based GFR was -3.0 ml per minute per 1.73 m2 per year with allopurinol and -2.5 ml per minute per 1.73 m2 per year with placebo (between-group difference, -0.6 ml per minute per 1.73 m2 per year; 95% CI, -1.5 to 0.4). The mean urinary albumin excretion rate after washout was 40% (95% CI, 0 to 80) higher with allopurinol than with placebo. The frequency of serious adverse events was simi

Published
2020

40. Abstracts of papers presented at the 14th conference of the Weed Science Society of Israel Abstracts of papers presented at the international conference on controlled atmosphere and fumigation (CAF) in stored products Abstracts of papers presented at the joint international conference of FAOPMA — CEPA on pest control in the 21st century Abstracts of papers presented at the 2nd international Agro-Ecology Symposium on integrated pest management: from the drawing board to the market: March 13, 1996 ARO, The Volcani Center, Bet Dagan, Israel April 21–26, 1996 Cyprus International Conference Centre, Nicosia, Cyprus May 8–12, 1996 Dan Panorama Hotel, Tel Aviv, Israel May 15,1996 Tel Aviv Convention Center, The Israel Trade Fairs Center, Tel Aviv, Israel

Author

Yogev, E., Berson, M., Benyamini, Y., Sheinboim, Y., Lev-Ran, T., Bahat, A., Barkai, Y., Gatti, Y., Zaidan, M., Barazani, O., Boshvize, Y., Graph, S., Luchinsky, U., Blumenfeld, T., Kleifeld, Y., Herzlinger, G., Bucsbaum, H., Golan, S., Chilf, T., Aly, R., Ohali, Y., Ovadia, A., Chachlon, Y., Yovel, H., Tesler, Y., Colodney, G., Nir, A., Zarka, S., Tal, A., Rubin, B., Yaacoby, T., Alon, Y., Kedar, Y., Assaraf, Orit Ben-Zvi, Shainberg, O., Rabinowitch, H. D., Tel-Or, E., Goldwasser, Y., Joel, D. M., Plakhine, D., Portnoy, V., Tzuri, G., Katzir, N., Losner-Goshen, Dalia, Mayer, A. M., Jacobsohn, R., Tanaami, Z., Eisenberg, H., Amsellem, Ziva, Kernyi, Z., Hornok, L., Gressel, J., Shomer-Ilan, Adiva, Nir, Ela, Michaeli, Daphna, Kampel, V., Warshawsky, A., Yogev, M., Negbi, M., Hershenhorn, J., Lavan, Y., Hilf, T., Horowitz, M., Cohen, M., Hirsch, I., Veneziani, A., Conyers, S. T., Bell, C. H., Sá-Fischer, Ana C., Adler, C. S., Reichmuth, Ch., Flinn, P. W., Hagstrum, D. W., Mbata, G. N., Winks, R. G., Hyne, Elisabeth A., Chaudhry, M. Q., MacNicoll, A. D., Price, N. R., Schöller, M., Dugast, J. -F., Plarre, R., Navarro, S., Donahaye, E. J., Diaz, R., Rindner, Miriam, Azrieli, A., Trematerra, P., Fontana, F., Mancini, M., Hocking, Ailsa D., Taniwaki, Marta H., Lacey, J., Hamer, A., Magan, N., Paster, N., Caliboso, F. M., Alvindia, D. G., Sabio, G. C., dela Cruz, M. T., Dharmaputra, Okky Setyawati, Putri, A. S. R., Sidik, M., Papademetriou, Eleni, Varnava, A., Mouskos, C., Malek, M. A., Parveen, B., Dzisi, K. A., Ellis, W. O., Estevez, Ana Maria, Galletti, Ljubica, Fichet, T., Oteiza, E., Lizana, L. A., Gonzalez, M. X., Yakobson, B., Slavezky, Y., Ephrati, H., Bartaly, El-H., Kashyap, R. K., Gupta, M., Kashyap, W. L., Dahiya, B. S., Dash, A. K., Rangaswamy, J. R., Shroff, R. D., Jayas, D. S., Muir, W. E., White, N. D. G., Gaye L, Weller, Graver, J. E. van S., Peng, Wu-Kang, Bengston, M., Alip, E., Reed, C., Leesch, J. G., Knapp, G. F., Russell, G. F., Llewellin, L. B., Ulrichs, Ch., Banks, H. J., Annis, P. C., Allanson, R., Tauscher, R., Westphal, K., Mohan, S., Gopalan, M., Sumdarababu, P. C., Narayanan, V. V. Sree, Prozell, Sabine, Ziegleder, G., Schartmann, B., Matissek, R., Kraus, J., Gerard, D., Rogg, S., Raemann, W., Ryan, R. F., Wang, Ya-Nan, Noyes, R. T., Kenkel, P., Criswell, J. T., Cuperus, G. W., Waterford, C. J., Whittle, C. P., Benzing, L., Ball, S., DeBruin, T., Newman, C. R., Hilton, S. J., Bridgeman, B. W., Hodges, R. J., Smith, M., Madden, A., Russell, D., Halid, H., Zettler, J. L., Sayaboc, Perlina D., Gibe, A. J. O., Ignatowicz, S., Oboza, S., Slusarski, C., Collins, P. J., El-Lakwah, F. A., Darwish, A. A., Khattab, M. M., Abdel-Latif, A. M., Emery, R. N., Pratt, S., Waterford, C., Clifton, A. L., Mills, K. A., Wontner-Smith, T. J., Khair, G., Magee, W. S., Baker, R. T., Taylor, R. W. D., Klijnstra, J., Ross, R. T., Donahaye, E. J., Kostokovski, M., Ducom, Valérie, Cassells, Julie A., Burton, R. H., Bhadrikaju, S., Meagher, R. L., Wilkin, R., van Natto, C., Stejskal, V., Cogan, P. M., Gratz, N. G., Shalom, U., Pener, Hedva, Havron, A. G., Klein, Z., Adler, H., Moran, S., Wilamowski, A., Amichai, R., Mueller, D. K., Spiegelstein, M., Shaaya, E., Kostjukovski, M., Cooper, N., Coll, M., Steinberg, S., Ravins, E., Waldner, W., Ausher, R., Rössler, Y., Denzer, H., Dunkelblum, E., and Kehat, M.

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results